ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
October 18 2021 - 6:34AM
Business Wire
New clinical research in ataxia-telangiectasia
(AT) patients finds nicotinamide riboside (NR) improved Ataxia
scores and increased antibody levels
ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings
from a first-of-its-kind clinical study published in the
peer-reviewed journal, Movement Disorders, conducted by Michèl
A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The
study investigated ChromaDex’s proprietary Niagen® ingredient
(patented nicotinamide riboside, or “NR”) in patients with
ataxia-telangiectasia (AT), a rare, inherited neurodegenerative
disorder characterized by premature aging, cerebellar degeneration,
immunodeficiency, and cancer predisposition. The study found that
supplementation with NR improved ataxia scores and increased
immunoglobulins, or antibodies, in the immune-compromised patients.
In addition to the findings, this was the first published clinical
NR trial to include participants under the age of 18, examining the
potential impact NR might have in children with AT.
“AT is a condition where children experience the negative
effects of premature aging with a very limited life expectancy,”
said Dr. Andrew Shao, ChromaDex Senior Vice President of Global
Scientific & Regulatory Affairs. “The results of this study are
promising for those living with AT and are consistent with previous
preclinical research. We look forward to the continued clinical
research exploring the impact of Niagen® on age-related health
declines.”
This study included 24 AT patients (15 males, 9 females), and 17
of the 24 were children under 18. The patients’ average age was
17.5 and no one in the study had previously supplemented with NR.
The group received 25mg/kg body weight of NR per day for four
consecutive months, followed by a two-month period without NR
treatment. The effects of NR on ataxia (a group of disorders that
affect coordination, balance and speech), dysarthria (a motor
speech disorder), quality of life, and laboratory parameters were
analyzed.
NR improved ataxia scores in patients and increased serum
immunoglobulin G (IgG), or antibodies, which are important for
protection against pathogens. Patients with AT are known to be
immunodeficient with decreased serum immunoglobulins
concentrations.
These results suggest that NAD+ boosting may be a potential
therapeutic strategy for AT, however further research needs to be
conducted.
For additional information on the science supporting Niagen®
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements related to results of the clinical studies,
their significance and potential impact of NR on those living with
AT. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211018005169/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024